Y
Yoshikazu Inoue
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 273
Citations - 17662
Yoshikazu Inoue is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 48, co-authored 233 publications receiving 12648 citations. Previous affiliations of Yoshikazu Inoue include Niigata University.
Papers
More filters
Journal Article
[Autopsy case of adenoid cystic carcinoma of the trachea: endobronchial treatment improves quality of life].
Kawaguchi T,Seiichi Nobuyama,Mituoka S,Toshihiko Sunami,Nobuyuki Naka,Kyoichi Okishio,Kiyonobu Ueno,S. Atagi,Yoshikazu Inoue,Mitsumasa Ogawara,Shigeto Hosoe,Yotsumoto S,Kawahara M,Keiji Iuchi,Satoru Yamamoto,Furuse K +15 more
TL;DR: It is concluded that endobronchial therapy such as stent placement or electrocautery is useful for maintaining good quality of life in a 67-year-old man with dyspnea.
Journal ArticleDOI
Severe clopidogrel-induced DRESS with eosinophilic pneumonia associated with Epstein-Barr virus reactivation.
TL;DR: The case of a 78‐year‐old man who presented with a rash, fever, dry cough, and swollen parotid glands who had been prescribed clopidogrel for one year is reported, and he was diagnosed with DRESS.
Journal ArticleDOI
Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan.
Fuminori Mizukoshi,Nobuyuki Kobayashi,Fumiko Kirikae,Ken Ohta,Kazunari Tsuyuguchi,Noritaka Yamada,Yoshikazu Inoue,Masahide Horiba,Noriko Kawata,Akiko Ichinose,Tohru Miyoshi-Akiyama,Reiko Kiritani,Keiji Funatogawa,Teruo Kirikae +13 more
TL;DR: In this article, the authors investigated the molecular epidemiological properties of drug-resistant tuberculosis in Japan and found that a significant number of multidrug-resistant M. tuberculosis strains were obtained from foreign-born patients from Asian countries with a high tuberculosis burden.
Effect of FEV1/FVC ratio on reduction in FVC decline with nintedanib in the INPULSIS™ trials
Martin Kolb,Yoshikazu Inoue,Ulrich Costabel,Paul Hernandez,Zelie Bailes,Rozsa Schlenker-Herceg,Arata Azuma +6 more
TL;DR: The two replicate randomized,placebo-controlled, 52-week Phase III INPULSIS™ trials assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with IPF.
Journal Article
A case of infected bulla caused by Mycobacterium kansasii
Seigo Minami,Katsuhiro Suzuki,Kazunari Tsuyuguchi,Hidenori Mawatari,Mayumi Suzuki,Tohru Arai,Yoshikazu Inoue,Seiji Hayashi,Norimitsu Sakatani +8 more
TL;DR: A 62-year-old man was referred to the authors' hospital because of persistent sub-fever and a pulmonary fungal infection was suspected owing to the elevation of the serum-D-glucan level.